- Mineralys Therapeutics reported that full Phase 2 Explore-CKD data for lorundrostat in uncontrolled hypertension with CKD and albuminuria were published in Kidney International, showing statistically significant reductions in systolic blood pressure and urinary albumin-to-creatinine ratio on top of guideline-directed therapy.
- The publication strengthens the clinical evidence base for lorundrostat in a high-risk cardiorenal population. This could matter for future label expansion efforts, pricing discussions and how much commercial value Mineralys Therapeutics might ultimately extract from its hypertension franchise.
- We will look at how Mineralys Therapeutics' investment narrative is shaped by Explore-CKD's blood pressure and albuminuria data in CKD patients.
Scan how Mineralys Therapeutics fits into the wider hypertension opportunity set by comparing it with other late-stage biotech plays in our hand-picked 19 high quality undiscovered gems list.
Mineralys Therapeutics Investment Narrative Recap
To own Mineralys Therapeutics, you need to believe lorundrostat can move from an R&D asset to an approved product in uncontrolled and resistant hypertension, then gradually into related cardiorenal settings. The core near term swing factor is progress toward filing and reviewing the first NDA, because the business currently reports no revenue and ongoing losses.
The new termination and payment agreements with Tanabe shift lorundrostat from a licensed asset to one Mineralys fully owns, while keeping milestone obligations in place. That mainly affects future economics and deal flexibility rather than the immediate regulatory path. As a result, the key short term risk remains regulatory delay or extra data requirements on the lead hypertension indication.
The October 27 agreements with Tanabe are the most relevant operational update here. Mineralys now holds the lorundrostat intellectual property directly instead of under a license, while still owing up to US$255 million in commercial milestones plus up to US$10 million for a second indication if those triggers are met, and with no material early termination penalties disclosed.
For you, this reshapes future upside and obligations more than near term catalysts. The NDA path in hypertension, the upcoming Q3 2026 results and commentary on cash runway, and the ability to fund late stage trials without heavy dilution stay in focus. The Japan right of first negotiation creates a clear framework if Mineralys chooses to partner that territory while pursuing broader cardiorenal indications.
Mineralys Therapeutics' current revenue is zero, while analysts are projecting revenue to reach US$463.2 million by 2029. This implies a very large ramp from today. Earnings are expected to shift from a loss of US$349.6 million today to a profit of US$15.2 million by 2029, a change of about US$365 million in earnings over that period.
Uncover why Mineralys Therapeutics' fair value indicates a 183% potential upside to its current price, which could narrow quickly.
Exploring Other Perspectives
One alternate angle to watch is competition risk. The most cautious analysts already assumed a tougher launch for Mineralys Therapeutics, with revenue of only US$152.4 million by 2029 and a more muted price target. That contrasts with the US$463.2 million consensus view and shows how quickly opinions could shift as the new Explore CKD and Tanabe agreements get digested.
Explore 2 other Mineralys Therapeutics fair value estimates, including one that suggests it could be worth just $45.22!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own analysis.
- A great starting point for your Mineralys Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- See our latest analysis for Mineralys Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easier to evaluate Mineralys Therapeutics' overall financial health at a glance.
Looking For More Investment Ideas Beyond Mineralys Therapeutics?
After reviewing Mineralys Therapeutics, it can help to widen your watchlist so you are not relying on a single thesis. The Simply Wall St Screener lets you filter for different types of opportunities and build a set of ideas that fits your own risk tolerance and time horizon.
- If capital preservation matters most, consider starting with companies that score well on balance sheet strength through our list of solid balance sheet and fundamentals (23 results).
- For investors hunting for quality businesses that might be trading at appealing valuations, use the 35 high quality undervalued stocks to see which stocks currently screen as both fundamentally strong and potentially mispriced.
- If steady income is your priority, focus on reliable payers by scanning the 4 dividend fortresses and build a watchlist of higher yielding options to research next.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com